. 2016 Mar 30;7(18):26709–26723. doi: 10.18632/oncotarget.8489

Table 3. Effects of galectin-1 and P38 inhibitor on the IC₅₀ of adriamycin and imatinib in K562, K562/Gal-1, and K562/ADM cells.

IC₅₀	K562/pc	K562/Gal-1	K562/ADM
IC₅₀	–	–	DMSO	SB202190	sc siRNA	Gal-1 siRNA	DMSO	SB202190
ADM(μg/ml)	0.485±0.03	1.676±0.145	1.636±0.141	1.29±0.125	25.56±0.41	14.76±0.45	26.51±0.44	16.24±0.48
imatinib(μM)	0.23±0.035	0.84±0.087	0.8±0.083	0.4±0.037	2.5±0.214	1.1±0.12	2.27±0.211	0.5±0.46

Table 3. Effects of galectin-1 and P38 inhibitor on the IC50 of adriamycin and imatinib in K562, K562/Gal-1, and K562/ADM cells.